12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Dara BioSciences, Mission Pharmacal sales and marketing update

Mission granted Dara exclusive commercialization rights in the U.S. to three marketed drugs - Ferralet for anemia, Binosto alendronate for osteoporosis and Aquoral for xerostomia. Additionally, Dara entered a deal with Mission's Alamo Pharma Services subsidiary to commercialize the drugs, along with three drugs from Dara - Soltamox tamoxifen for breast cancer, Gelclair...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >